Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 2, 2011, Pages 162-168

  Yenny, ^a   Nafrialdi, ^b   Djoerban, Z ^b   Setiabudy, R ^b  

^a TRISAKTI UNIVERSITY   (Indonesia)

^b UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

Efavirenz; Interaction; Rifampicin; Volunteers

Indexed keywords

EFAVIRENZ; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INDONESIA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; BENZOXAZINES; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; RIFAMPIN;

EID: 78751688258     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201473     Document Type: Article

References (20)

1. Djoerban Z. AIDS: from basic knowledge to HIV-TB co-infection. Acta Med Indones. 2008; 40: 113.
2. Clain KP, Anekthananon T, Burapat C, et al. Causes of death in HIV-infected persons who have tuberculosis. Thailand Emerg Infect Dis. 2009; 15: 258-264.
3. Sumantri S, Djoerban Z. Clinical manifestations and antiretroviral management of HIV/AIDS patients with tuberculosis co-infection in Kramat 128 hospital. Acta Med Indones. 2008; 40: 117-123
4. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicenter randomized trial. Lancet. 2004; 364: 1244-1251.
5. Burman WJ. Issues in the management of HIV-related tuberculosis. Clin Chest Med. 2005; 26: 283-294.
6. Friedland G, Khoo S, Jack C, et al. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. Antimicrob Agents Chemother. 2006; 58: 1299-1302.
7. Lopez-Cortez LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002; 41: 681-690.
8. Manosuthi W, Sungkanuparph S, Thakkinstia A, et al. Efavirenz levels and 24-weeks efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS. 2005; 19: 1481-1486.
9. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 2006; 20: 131-132. (Pubitemid 41818129)
10. Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, et al. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 2005; 19: 1541-1543. (Pubitemid 41400701)
11. DiGiacinto JL, Chan-Tack KM, Robertson SM, et al. Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampicin. J Clin Pharmacol 2008; 48: 518-523.
12. Benedek I, Joshi A, Fiske WD, et al. Pharmacokinetic interaction between efavirenz (EFV) and rifampicin (RIF) in healthy volunteers. XII International Conference on AIDS. Geneva: 1998. (abstract 42280).
13. Ahsan CH, Renwick AG, Macklin B, et al. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmac. 1991; 31: 399-403.
14. Joshi AS, Barrett JS, Fiske WD, et al. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy. 39th Interscience Conference on Antimicrob Agents Chemotherapy. San Francisco: American Society for Microbiology. September 1999 [Poster 12011].
15. Marzolini C, Talenti A, Decostered LA, et al. Efavirenz plasma level can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS. 2001; 15: 71-5.
16. Almond LM, Hoggard PG, Edirisinghe D, et al. Intracelluler and plasma pharmacokinetics of efavirenz in HIV-infected individuals. Antimicrob Agents Chemother. 2005; 56: 736-744.
17. Tanaka R, Hanabusa H, Kinai E, et al. Intracellular efavirenz levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals. Antimicrob Agents Chemother. 2008; 52: 782-785.
18. Sustiva (efavirenz). Bristol-Myers Squibb: products. Revised November 2009. [online]. Available from http://www.bms.com. [accessed November 23, 2009].
19. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. Antimicrob Agents Chemother 2009; 64: 910-928.
20. Food and Drug Administration. Center for Drug Evaluation (CDER). Guidance for Industry: In vivo drug metabolism/drug interaction studies-study design, data analysis, and recomendations for dosing and labeling. 1999. [online] Available from http://www.fda.gov/cder/guidance/index.htm. [accessed October 28, 2009].